Proprietary Name,NDC Package Code,Strength,Dosage Form,Route,Appl. No.,Labeler Name,Product NDC,Nonproprietary Name,Substance Name,Product Type Name,Start Marketing Date,End Marketing Date,Market Category,Package Description,Pharm Class,DEA,Sample Package,Listing Record Certified Through:
ZIAGEN,49702-0221-18,300 mg/1,"TABLET, FILM COATED",ORAL,NDA020977,ViiV Healthcare Company,49702-221,abacavir sulfate,ABACAVIR SULFATE,HUMAN PRESCRIPTION DRUG,12/29/1998,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-221-18)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
ZIAGEN,49702-0222-48,20 mg/mL,SOLUTION,ORAL,NDA020978,ViiV Healthcare Company,49702-222,abacavir sulfate,ABACAVIR SULFATE,HUMAN PRESCRIPTION DRUG,1/28/1999,N/A,NDA,1 BOTTLE in 1 CARTON (49702-222-48)  > 240 mL in 1 BOTTLE,"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Emtriva,70518-1847-00,200 mg/1,CAPSULE,ORAL,NDA021500,REMEDYREPACK INC.,70518-1847,EMTRICITABINE,EMTRICITABINE,HUMAN PRESCRIPTION DRUG,2/4/2019,N/A,NDA,4 CAPSULE in 1 BLISTER PACK (70518-1847-0),"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Emtriva,61958-0602-01,10 mg/mL,SOLUTION,ORAL,NDA021896,"Gilead Sciences, Inc.",61958-0602,EMTRICITABINE,EMTRICITABINE,HUMAN PRESCRIPTION DRUG,9/28/2005,N/A,NDA,"1 BOTTLE, DISPENSING in 1 CARTON (61958-0602-1)  > 170 mL in 1 BOTTLE, DISPENSING","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Emtriva,61958-0601-01,200 mg/1,CAPSULE,ORAL,NDA021500,"Gilead Sciences, Inc.",61958-0601,EMTRICITABINE,EMTRICITABINE,HUMAN PRESCRIPTION DRUG,7/2/2003,N/A,NDA,"30 CAPSULE in 1 BOTTLE, PLASTIC (61958-0601-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
EPIVIR,00173-0662-00,100 mg/1,"TABLET, FILM COATED",ORAL,NDA021003,GlaxoSmithKline LLC,0173-0662,lamivudine,LAMIVUDINE,HUMAN PRESCRIPTION DRUG,12/17/1998,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (0173-0662-00)","Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
EPIVIR,00173-0663-00,5 mg/mL,SOLUTION,ORAL,NDA021004,GlaxoSmithKline LLC,0173-0663,lamivudine,LAMIVUDINE,HUMAN PRESCRIPTION DRUG,12/23/1998,N/A,NDA,240 mL in 1 BOTTLE (0173-0663-00),"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
EPIVIR,49702-0205-48,10 mg/mL,SOLUTION,ORAL,NDA020596,ViiV Healthcare Company,49702-205,lamivudine,LAMIVUDINE,HUMAN PRESCRIPTION DRUG,10/4/2010,N/A,NDA,240 mL in 1 BOTTLE (49702-205-48),"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
EPIVIR,49702-0203-18,150 mg/1,"TABLET, FILM COATED",ORAL,NDA020564,ViiV Healthcare Company,49702-203,lamivudine,LAMIVUDINE,HUMAN PRESCRIPTION DRUG,10/4/2010,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-203-18)","Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
EPIVIR,49702-0204-13,300 mg/1,"TABLET, FILM COATED",ORAL,NDA020564,ViiV Healthcare Company,49702-204,lamivudine,LAMIVUDINE,HUMAN PRESCRIPTION DRUG,10/4/2010,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-204-13)","Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Viread,61958-0404-01,150 mg/1,"TABLET, COATED",ORAL,NDA021356,"Gilead Sciences, Inc.",61958-0404,TENOFOVIR DISOPROXIL FUMARATE,TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,1/18/2012,N/A,NDA,"30 TABLET, COATED in 1 BOTTLE, PLASTIC (61958-0404-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Viread,61958-0405-01,200 mg/1,"TABLET, COATED",ORAL,NDA021356,"Gilead Sciences, Inc.",61958-0405,TENOFOVIR DISOPROXIL FUMARATE,TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,1/18/2012,N/A,NDA,"30 TABLET, COATED in 1 BOTTLE, PLASTIC (61958-0405-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Viread,50090-0754-00,300 mg/1,"TABLET, COATED",ORAL,NDA021356,A-S Medication Solutions,50090-0754,TENOFOVIR DISOPROXIL FUMARATE,TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,10/26/2001,N/A,NDA,"30 TABLET, COATED in 1 BOTTLE, PLASTIC (50090-0754-0)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Viread,61958-0406-01,250 mg/1,"TABLET, COATED",ORAL,NDA021356,"Gilead Sciences, Inc.",61958-0406,TENOFOVIR DISOPROXIL FUMARATE,TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,1/18/2012,N/A,NDA,"30 TABLET, COATED in 1 BOTTLE, PLASTIC (61958-0406-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Viread,61958-0401-01,300 mg/1,"TABLET, COATED",ORAL,NDA021356,"Gilead Sciences, Inc.",61958-0401,TENOFOVIR DISOPROXIL FUMARATE,TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,10/26/2001,N/A,NDA,"30 TABLET, COATED in 1 BOTTLE, PLASTIC (61958-0401-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Viread,61958-0403-01,40 mg/g,POWDER,ORAL,NDA022577,"Gilead Sciences, Inc.",61958-0403,TENOFOVIR DISOPROXIL FUMARATE,TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,1/18/2012,N/A,NDA,"1 BOTTLE, PLASTIC in 1 CARTON (61958-0403-1)  > 60 g in 1 BOTTLE, PLASTIC","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
RETROVIR,49702-0211-20,100 mg/1,CAPSULE,ORAL,NDA019655,ViiV Healthcare Company,49702-211,zidovudine,ZIDOVUDINE,HUMAN PRESCRIPTION DRUG,10/28/2010,N/A,NDA,100 CAPSULE in 1 BOTTLE (49702-211-20),"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
RETROVIR,49702-0213-26,10 mg/mL,"INJECTION, SOLUTION",INTRAVENOUS,NDA019951,ViiV Healthcare Company,49702-213,zidovudine,ZIDOVUDINE,HUMAN PRESCRIPTION DRUG,11/4/2010,N/A,NDA,"5 VIAL, SINGLE-USE in 1 CARTON (49702-213-26)  > 20 mL in 1 VIAL, SINGLE-USE (49702-213-01)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
RETROVIR,49702-0212-48,10 mg/mL,SOLUTION,ORAL,NDA019910,ViiV Healthcare Company,49702-212,zidovudine,ZIDOVUDINE,HUMAN PRESCRIPTION DRUG,10/28/2010,N/A,NDA,240 mL in 1 BOTTLE (49702-212-48),"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
PIFELTRO,00006-3069-01,100 mg/1,"TABLET, FILM COATED",ORAL,NDA210806,Merck Sharp & Dohme Corp.,0006-3069,doravirine,DORAVIRINE,HUMAN PRESCRIPTION DRUG,7/20/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (0006-3069-01)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Non-Nucleoside Analog [EXT]",N/A,No,12/31/2020
SUSTIVA,00056-0470-30,50 mg/1,"CAPSULE, GELATIN COATED",ORAL,NDA020972,Bristol-Myers Squibb Pharma Company,0056-0470,Efavirenz,EFAVIRENZ,HUMAN PRESCRIPTION DRUG,9/17/1998,N/A,NDA,"30 CAPSULE, GELATIN COATED in 1 BOTTLE (0056-0470-30)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA]",N/A,No,12/31/2020
SUSTIVA,00056-0474-92,200 mg/1,"CAPSULE, GELATIN COATED",ORAL,NDA020972,Bristol-Myers Squibb Pharma Company,0056-0474,efavirenz,EFAVIRENZ,HUMAN PRESCRIPTION DRUG,9/17/1998,N/A,NDA,"90 CAPSULE, GELATIN COATED in 1 BOTTLE (0056-0474-92)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA]",N/A,No,12/31/2020
SUSTIVA,00056-0510-30,600 mg/1,"TABLET, FILM COATED",ORAL,NDA021360,Bristol-Myers Squibb Pharma Company,0056-0510,efavirenz,EFAVIRENZ,HUMAN PRESCRIPTION DRUG,1/2/2002,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (0056-0510-30)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA]",N/A,No,12/31/2020
Intelence,59676-0571-01,200 mg/1,TABLET,ORAL,NDA022187,Janssen Products LP,59676-571,etravirine,ETRAVIRINE,HUMAN PRESCRIPTION DRUG,12/22/2010,N/A,NDA,"60 TABLET in 1 BOTTLE, PLASTIC (59676-571-01)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Intelence,59676-0572-01,25 mg/1,TABLET,ORAL,NDA022187,Janssen Products LP,59676-572,etravirine,ETRAVIRINE,HUMAN PRESCRIPTION DRUG,3/26/2012,N/A,NDA,"120 TABLET in 1 BOTTLE, PLASTIC (59676-572-01)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Intelence,59676-0570-01,100 mg/1,TABLET,ORAL,NDA022187,Janssen Products LP,59676-570,etravirine,ETRAVIRINE,HUMAN PRESCRIPTION DRUG,1/18/2008,N/A,NDA,"120 TABLET in 1 BOTTLE, PLASTIC (59676-570-01)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Viramune,00597-0123-30,400 mg/1,"TABLET, EXTENDED RELEASE",ORAL,NDA201152,"Boehringer Ingelheim Pharmaceuticals, Inc.",0597-0123,nevirapine,NEVIRAPINE,HUMAN PRESCRIPTION DRUG,4/11/2011,N/A,NDA,"30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0123-30)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA]",N/A,No,12/31/2020
Viramune,00597-0046-60,200 mg/1,TABLET,ORAL,NDA020636,Boehringer Ingelheim Pharmaceuticals Inc.,0597-0046,nevirapine,NEVIRAPINE,HUMAN PRESCRIPTION DRUG,8/1/2001,N/A,NDA,60 TABLET in 1 BOTTLE (0597-0046-60),"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA]",N/A,No,12/31/2020
Viramune,00597-0047-24,50 mg/5mL,SUSPENSION,ORAL,NDA020933,Boehringer Ingelheim Pharmaceuticals Inc.,0597-0047,nevirapine,NEVIRAPINE,HUMAN PRESCRIPTION DRUG,10/1/2001,N/A,NDA,"1 BOTTLE, PLASTIC in 1 CARTON (0597-0047-24)  > 240 mL in 1 BOTTLE, PLASTIC","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA]",N/A,No,12/31/2020
Viramune XR (extended release),N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,                               N/A,N/A,N/A,N/A,N/A,                               N/A,N/A,                                                    N/A
EDURANT,59676-0278-01,25 mg/1,"TABLET, FILM COATED",ORAL,NDA202022,"Janssen Products, LP",59676-278,rilpivirine hydrochloride,RILPIVIRINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,5/20/2011,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (59676-278-01)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Non-Nucleoside Analog [EXT]",N/A,No,12/31/2021
REYATAZ,00003-3631-12,200 mg/1,"CAPSULE, GELATIN COATED",ORAL,NDA021567,"E.R. Squibb & Sons, L.L.C.",0003-3631,ATAZANAVIR,ATAZANAVIR SULFATE,HUMAN PRESCRIPTION DRUG,6/24/2003,N/A,NDA,"60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3631-12)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UGT1A1 Inhibitors [MoA], UDP Glucuronosyltransferases Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA]",N/A,No,12/31/2020
REYATAZ,00003-3638-10,50 mg/1,POWDER,ORAL,NDA206352,"E.R. Squibb & Sons, L.L.C.",0003-3638,ATAZANAVIR,ATAZANAVIR SULFATE,HUMAN PRESCRIPTION DRUG,12/19/2014,N/A,NDA,30 PACKET in 1 CARTON (0003-3638-10)  > 1 POWDER in 1 PACKET,"HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UGT1A1 Inhibitors [MoA], UDP Glucuronosyltransferases Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA]",N/A,No,12/31/2020
REYATAZ,67296-1236-04,300 mg/1,"CAPSULE, GELATIN COATED",ORAL,NDA021567,"RedPharm Drug, Inc.",67296-1236,REYATAZ,ATAZANAVIR SULFATE,HUMAN PRESCRIPTION DRUG,6/24/2003,N/A,NDA,"4 CAPSULE, GELATIN COATED in 1 BOTTLE (67296-1236-4)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UGT1A1 Inhibitors [MoA], UDP Glucuronosyltransferases Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA]",N/A,No,12/31/2021
REYATAZ,00003-3622-12,300 mg/1,"CAPSULE, GELATIN COATED",ORAL,NDA021567,"E.R. Squibb & Sons, L.L.C.",0003-3622,ATAZANAVIR,ATAZANAVIR SULFATE,HUMAN PRESCRIPTION DRUG,6/24/2003,N/A,NDA,"30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3622-12)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UGT1A1 Inhibitors [MoA], UDP Glucuronosyltransferases Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA]",N/A,No,12/31/2020
REYATAZ,00003-3624-12,150 mg/1,"CAPSULE, GELATIN COATED",ORAL,NDA021567,"E.R. Squibb & Sons, L.L.C.",0003-3624,ATAZANAVIR,ATAZANAVIR SULFATE,HUMAN PRESCRIPTION DRUG,6/24/2003,N/A,NDA,"60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3624-12)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UGT1A1 Inhibitors [MoA], UDP Glucuronosyltransferases Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA]",N/A,No,12/31/2020
PREZISTA (U),53808-0773-01, , , , ,State of Florida DOH Central Pharmacy, , , , , ,N/A, , ,N/A,N/A,N/A, 
PREZISTA,59676-0562-01,600 mg/1,"TABLET, FILM COATED",ORAL,NDA021976,Janssen Products LP,59676-562,darunavir,DARUNAVIR ETHANOLATE,HUMAN PRESCRIPTION DRUG,3/8/2008,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (59676-562-01)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA]",N/A,No,12/31/2021
PREZISTA,59676-0563-01,75 mg/1,"TABLET, FILM COATED",ORAL,NDA021976,Janssen Products LP,59676-563,darunavir,DARUNAVIR ETHANOLATE,HUMAN PRESCRIPTION DRUG,1/14/2009,N/A,NDA,"480 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (59676-563-01)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA]",N/A,No,12/31/2021
PREZISTA,59676-0564-01,150 mg/1,"TABLET, FILM COATED",ORAL,NDA021976,Janssen Products LP,59676-564,darunavir,DARUNAVIR ETHANOLATE,HUMAN PRESCRIPTION DRUG,4/27/2009,N/A,NDA,"240 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (59676-564-01)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA]",N/A,No,12/31/2021
PREZISTA,59676-0565-01,100 mg/mL,SUSPENSION,ORAL,NDA202895,Janssen Products LP,59676-565,darunavir,DARUNAVIR ETHANOLATE,HUMAN PRESCRIPTION DRUG,12/16/2011,N/A,NDA,"1 BOTTLE, GLASS in 1 CARTON (59676-565-01)  > 200 mL in 1 BOTTLE, GLASS","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA]",N/A,No,12/31/2021
PREZISTA,59676-0566-30,800 mg/1,"TABLET, FILM COATED",ORAL,NDA021976,Janssen Products LP,59676-566,darunavir,DARUNAVIR ETHANOLATE,HUMAN PRESCRIPTION DRUG,11/9/2012,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (59676-566-30)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA]",N/A,No,12/31/2021
PREZISTA,70518-1483-00,800 mg/1,"TABLET, FILM COATED",ORAL,NDA021976,REMEDYREPACK INC.,70518-1483,darunavir,DARUNAVIR ETHANOLATE,HUMAN PRESCRIPTION DRUG,10/6/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (70518-1483-0)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA]",N/A,No,12/31/2020
LEXIVA,49702-0208-53,50 mg/mL,SUSPENSION,ORAL,NDA022116,ViiV Healthcare Company,49702-208,fosamprenavir calcium,FOSAMPRENAVIR CALCIUM,HUMAN PRESCRIPTION DRUG,10/4/2010,N/A,NDA,225 mL in 1 BOTTLE (49702-208-53),"Protease Inhibitor [EPC], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], P-Glycoprotein Inducers [MoA], HIV Protease Inhibitors [MoA]",N/A,No,12/31/2021
LEXIVA,49702-0207-18,700 mg/1,"TABLET, FILM COATED",ORAL,NDA021548,ViiV Healthcare Company,49702-207,fosamprenavir calcium,FOSAMPRENAVIR CALCIUM,HUMAN PRESCRIPTION DRUG,10/4/2010,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-207-18)","Protease Inhibitor [EPC], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], P-Glycoprotein Inducers [MoA], HIV Protease Inhibitors [MoA]",N/A,No,12/31/2021
Norvir,00074-3333-30,100 mg/1,"TABLET, FILM COATED",ORAL,NDA022417,AbbVie Inc.,0074-3333,Ritonavir,RITONAVIR,HUMAN PRESCRIPTION DRUG,5/6/2010,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (0074-3333-30)","HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Norvir,00074-3399-30,100 mg/1,POWDER,ORAL,NDA209512,AbbVie Inc.,0074-3399,Ritonavir,RITONAVIR,HUMAN PRESCRIPTION DRUG,6/7/2017,N/A,NDA,30 PACKET in 1 CARTON (0074-3399-30)  > 1 POWDER in 1 PACKET,"HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Norvir,67296-1234-04,100 mg/1,"TABLET, FILM COATED",ORAL,NDA022417,"RedPharm Drug, Inc.",67296-1234,Norvir,RITONAVIR,HUMAN PRESCRIPTION DRUG,5/6/2010,N/A,NDA,"4 TABLET, FILM COATED in 1 BOTTLE (67296-1234-4)","HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Norvir,00074-1940-63,80 mg/mL,SOLUTION,ORAL,NDA020659,AbbVie Inc.,0074-1940,Ritonavir,RITONAVIR,HUMAN PRESCRIPTION DRUG,5/6/2010,N/A,NDA,1 BOTTLE in 1 CARTON (0074-1940-63)  > 240 mL in 1 BOTTLE,"HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Norvir,53808-1119-01,100 mg/1,"TABLET, FILM COATED",ORAL,NDA022417,DOH CENTRAL PHARMACY,53808-1119,Ritonavir,RITONAVIR,HUMAN PRESCRIPTION DRUG,1/9/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (53808-1119-1)","HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2020
Invirase,00004-0244-51,500 mg/1,"TABLET, FILM COATED",ORAL,NDA021785,"Genentech, Inc.",0004-0244,saquinavir mesylate,SAQUINAVIR MESYLATE,HUMAN PRESCRIPTION DRUG,12/17/2004,N/A,NDA,"120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0004-0244-51)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA]",N/A,No,12/31/2021
Invirase,00004-0245-15,200 mg/1,CAPSULE,ORAL,NDA020628,"Genentech, Inc.",0004-0245,saquinavir mesylate,SAQUINAVIR MESYLATE,HUMAN PRESCRIPTION DRUG,12/6/1995,N/A,NDA,"270 CAPSULE in 1 BOTTLE, PLASTIC (0004-0245-15)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA]",N/A,No,12/31/2021
Aptivus,00597-0002-01,100 mg/mL,SOLUTION,ORAL,NDA022292,"Boehringer Ingelheim Pharmaceuticals, Inc.",0597-0002,tipranavir,TIPRANAVIR,HUMAN PRESCRIPTION DRUG,9/1/2008,N/A,NDA,"1 BOTTLE, GLASS in 1 CARTON (0597-0002-01)  > 95 mL in 1 BOTTLE, GLASS","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC]",N/A,No,12/31/2021
Aptivus,00597-0003-02,250 mg/1,"CAPSULE, LIQUID FILLED",ORAL,NDA021814,"Boehringer Ingelheim Pharmaceuticals, Inc.",0597-0003,tipranavir,TIPRANAVIR,HUMAN PRESCRIPTION DRUG,7/1/2005,N/A,NDA,"120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (0597-0003-02)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC]",N/A,No,12/31/2021
FUZEON,00004-0381-40,,KIT,,NDA021481,"Genentech, Inc.",0004-0381,Enfuvirtide,,HUMAN PRESCRIPTION DRUG,4/10/2012,N/A,NDA,"1 KIT in 1 CARTON (0004-0381-40)  *  1 mL in 1 VIAL, SINGLE-USE *  1 mL in 1 VIAL, SINGLE-DOSE",N/A,N/A,No,12/31/2021
SELZENTRY,49702-0235-08,75 mg/1,"TABLET, FILM COATED",ORAL,NDA022128,ViiV Healthcare Company,49702-235,maraviroc,MARAVIROC,HUMAN PRESCRIPTION DRUG,11/4/2016,N/A,NDA,"120 TABLET, FILM COATED in 1 BOTTLE (49702-235-08)","CCR5 Co-receptor Antagonist [EPC], Chemokine Co-receptor 5 Antagonists [MoA]",N/A,No,12/31/2021
SELZENTRY,49702-0237-55,20 mg/mL,SOLUTION,ORAL,NDA208984,ViiV Healthcare Company,49702-237,maraviroc,MARAVIROC,HUMAN PRESCRIPTION DRUG,11/4/2016,N/A,NDA,1 BOTTLE in 1 CARTON (49702-237-55)  > 230 mL in 1 BOTTLE,"CCR5 Co-receptor Antagonist [EPC], Chemokine Co-receptor 5 Antagonists [MoA]",N/A,No,12/31/2021
SELZENTRY,49702-0223-18,150 mg/1,"TABLET, FILM COATED",ORAL,NDA022128,ViiV Healthcare Company,49702-223,maraviroc,MARAVIROC,HUMAN PRESCRIPTION DRUG,5/16/2011,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-223-18)","CCR5 Co-receptor Antagonist [EPC], Chemokine Co-receptor 5 Antagonists [MoA]",N/A,No,12/31/2021
SELZENTRY,49702-0224-18,300 mg/1,"TABLET, FILM COATED",ORAL,NDA022128,ViiV Healthcare Company,49702-224,maraviroc,MARAVIROC,HUMAN PRESCRIPTION DRUG,5/16/2011,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-224-18)","CCR5 Co-receptor Antagonist [EPC], Chemokine Co-receptor 5 Antagonists [MoA]",N/A,No,12/31/2021
SELZENTRY,49702-0233-08,25 mg/1,"TABLET, FILM COATED",ORAL,NDA022128,ViiV Healthcare Company,49702-233,maraviroc,MARAVIROC,HUMAN PRESCRIPTION DRUG,11/4/2016,N/A,NDA,"120 TABLET, FILM COATED in 1 BOTTLE (49702-233-08)","CCR5 Co-receptor Antagonist [EPC], Chemokine Co-receptor 5 Antagonists [MoA]",N/A,No,12/31/2021
Tivicay,49702-0226-13,10 mg/1,"TABLET, FILM COATED",ORAL,NDA204790,ViiV Healthcare Company,49702-226,dolutegravir sodium,DOLUTEGRAVIR SODIUM,HUMAN PRESCRIPTION DRUG,6/9/2016,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-226-13)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA]",N/A,No,12/31/2021
Tivicay,49702-0227-13,25 mg/1,"TABLET, FILM COATED",ORAL,NDA204790,ViiV Healthcare Company,49702-227,dolutegravir sodium,DOLUTEGRAVIR SODIUM,HUMAN PRESCRIPTION DRUG,6/9/2016,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-227-13)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA]",N/A,No,12/31/2021
Tivicay,53808-1130-01,50 mg/1,"TABLET, FILM COATED",ORAL,NDA204790,DOH CENTRAL PHARMACY,53808-1130,dolutegravir sodium,DOLUTEGRAVIR SODIUM,HUMAN PRESCRIPTION DRUG,7/10/2017,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (53808-1130-1)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA]",N/A,No,12/31/2020
Tivicay,70518-1487-01,50 mg/1,"TABLET, FILM COATED",ORAL,NDA204790,REMEDYREPACK INC.,70518-1487,dolutegravir sodium,DOLUTEGRAVIR SODIUM,HUMAN PRESCRIPTION DRUG,10/6/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (70518-1487-0)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA]",N/A,No,12/31/2020
Tivicay,49702-0228-13,50 mg/1,"TABLET, FILM COATED",ORAL,NDA204790,ViiV Healthcare Company,49702-228,dolutegravir sodium,DOLUTEGRAVIR SODIUM,HUMAN PRESCRIPTION DRUG,8/13/2013,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-228-13)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA]",N/A,No,12/31/2021
Tivicay PD,49702-0255-37,5 mg/1,"TABLET, FOR SUSPENSION",ORAL,NDA213983,ViiV Healthcare Company,49702-255,dolutegravir sodium,DOLUTEGRAVIR SODIUM,HUMAN PRESCRIPTION DRUG,6/12/2020,N/A,NDA,"1 BOTTLE in 1 CARTON (49702-255-37)  > 60 TABLET, FOR SUSPENSION in 1 BOTTLE","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA]",N/A,No,12/31/2021
ISENTRESS,70518-1621-01,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,REMEDYREPACK INC.,70518-1621,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/31/2018,N/A,NDA,"6 TABLET, FILM COATED in 1 BLISTER PACK (70518-1621-1)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
ISENTRESS,70518-1621-00,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,REMEDYREPACK INC.,70518-1621,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/31/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (70518-1621-0)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
ISENTRESS,70518-1621-02,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,REMEDYREPACK INC.,70518-1621,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/31/2018,N/A,NDA,"8 TABLET, FILM COATED in 1 BLISTER PACK (70518-1621-2)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
ISENTRESS,00006-0473-61,25 mg/1,"TABLET, CHEWABLE",ORAL,NDA203045,Merck Sharp & Dohme Corp.,0006-0473,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,12/21/2011,N/A,NDA,"60 TABLET, CHEWABLE in 1 BOTTLE (0006-0473-61)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,00006-0227-61,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,Merck Sharp & Dohme Corp.,0006-0227,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (0006-0227-61)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,00006-0477-61,100 mg/1,"TABLET, CHEWABLE",ORAL,NDA203045,Merck Sharp & Dohme Corp.,0006-0477,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,12/21/2011,N/A,NDA,"60 TABLET, CHEWABLE in 1 BOTTLE (0006-0477-61)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,68071-2113-06,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,"NuCare Pharmaceuticals,Inc.",68071-2113,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"6 TABLET, FILM COATED in 1 BOTTLE (68071-2113-6)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
ISENTRESS,00006-3603-60,100 mg/1,"GRANULE, FOR SUSPENSION",ORAL,NDA205786,Merck Sharp & Dohme Corp.,0006-3603,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,12/20/2013,N/A,NDA,"60 PACKET in 1 CARTON (0006-3603-60)  > 1 GRANULE, FOR SUSPENSION in 1 PACKET (0006-3603-01)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,00006-3603-61,100 mg/1,"GRANULE, FOR SUSPENSION",ORAL,NDA205786,Merck Sharp & Dohme Corp.,0006-3603,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,12/20/2013,N/A,NDA,"60 PACKET in 1 CARTON (0006-3603-61)  > 1 GRANULE, FOR SUSPENSION in 1 PACKET (0006-3603-01)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,61919-0706-02,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,Direct_Rx,61919-706,ISENTRESS,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,8/13/2019,N/A,NDA,"2 TABLET, FILM COATED in 1 BOTTLE (61919-706-02)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,00006-3080-01,600 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,Merck Sharp & Dohme Corp.,0006-3080,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,5/26/2017,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (0006-3080-01)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,50090-1085-01,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,A-S Medication Solutions,50090-1085,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"8 TABLET, FILM COATED in 1 BOTTLE (50090-1085-1)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
ISENTRESS,50090-1085-02,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,A-S Medication Solutions,50090-1085,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"6 TABLET, FILM COATED in 1 BOTTLE (50090-1085-2)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
ISENTRESS,67296-1235-08,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,"RedPharm Drug, Inc.",67296-1235,ISENTRESS,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"8 TABLET, FILM COATED in 1 BOTTLE (67296-1235-8)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,67296-1235-06,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,"RedPharm Drug, Inc.",67296-1235,ISENTRESS,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"6 TABLET, FILM COATED in 1 BOTTLE (67296-1235-6)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2021
ISENTRESS,50090-1085-00,400 mg/1,"TABLET, FILM COATED",ORAL,NDA022145,A-S Medication Solutions,50090-1085,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,HUMAN PRESCRIPTION DRUG,10/12/2007,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (50090-1085-0)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]",N/A,No,12/31/2020
Isentress HD ,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
Rukobia,49702-0250-18,600 mg/1,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,NDA212950,ViiV Healthcare Company,49702-250,fostemsavir tromethamine,FOSTEMSAVIR TROMETHAMINE,HUMAN PRESCRIPTION DRUG,7/2/2020,N/A,NDA,"1 BOTTLE in 1 CARTON (49702-250-18)  > 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE",N/A,N/A,No,12/31/2021
TROGARZO,62064-0122-02,150 mg/mL,"INJECTION, SOLUTION",INTRAVENOUS,BLA761065,Theratechnologies Inc.,62064-122,ibalizumab,IBALIZUMAB,HUMAN PRESCRIPTION DRUG,4/20/2018,N/A,BLA,"2 VIAL, SINGLE-USE in 1 CARTON (62064-122-02)  > 1.33 mL in 1 VIAL, SINGLE-USE (62064-122-01)",N/A,N/A,No,12/31/2021
Tybost,61958-1401-01,150 mg/1,"TABLET, FILM COATED",ORAL,NDA203094,"Gilead Sciences, Inc.",61958-1401,COBICISTAT,COBICISTAT,HUMAN PRESCRIPTION DRUG,9/24/2014,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (61958-1401-1)","Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA]",N/A,No,12/31/2020
EPZICOM,49702-0206-13,"600 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021652,ViiV Healthcare Company,49702-206,abacavir sulfate and lamivudine,ABACAVIR SULFATE;  LAMIVUDINE,HUMAN PRESCRIPTION DRUG,10/12/2010,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-206-13)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Triumeq,49702-0231-13,"600 mg/1,                         50  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA205551,ViiV Healthcare Company,49702-231,"abacavir sulfate, dolutegravir sodium, lamivudine",ABACAVIR SULFATE;  DOLUTEGRAVIR SODIUM;  LAMIVUDINE,HUMAN PRESCRIPTION DRUG,8/22/2014,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-231-13)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
TRIZIVIR,49702-0217-18,"300 mg/1,                         150  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021205,ViiV Healthcare Company,49702-217,"abacavir sulfate, lamivudine, and zidovudine",ABACAVIR SULFATE;  LAMIVUDINE;  ZIDOVUDINE,HUMAN PRESCRIPTION DRUG,11/2/2010,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-217-18)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
EVOTAZ,00003-3641-11,"300 mg/1,                         150  mg/1",TABLET,ORAL,NDA206353,"E.R. Squibb & Sons, L.L.C.",0003-3641,atazanavir and cobicistat,ATAZANAVIR SULFATE;  COBICISTAT,HUMAN PRESCRIPTION DRUG,1/29/2015,N/A,NDA,30 TABLET in 1 BOTTLE (0003-3641-11),"HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UGT1A1 Inhibitors [MoA], UDP Glucuronosyltransferases Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA]",N/A,No,12/31/2021
Biktarvy,61958-2501-01,"50 mg/1,                         200  mg/1,                         25  mg/1",TABLET,ORAL,NDA210251,"Gilead Sciences, Inc.",61958-2501,"bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate",BICTEGRAVIR SODIUM;  EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,2/7/2018,N/A,NDA,"30 TABLET in 1 BOTTLE, PLASTIC (61958-2501-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Biktarvy,61958-2501-02,"50 mg/1,                         200  mg/1,                         25  mg/1",TABLET,ORAL,NDA210251,"Gilead Sciences, Inc.",61958-2501,"bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate",BICTEGRAVIR SODIUM;  EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,2/7/2018,N/A,NDA,"7 TABLET in 1 BOTTLE, PLASTIC (61958-2501-2)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
PREZCOBIX,59676-0575-30,"800 mg/1,                         150  mg/1","TABLET, FILM COATED",ORAL,NDA205395,Janssen Products LP,59676-575,DARUNAVIR ETHANOLATE and COBICISTAT,DARUNAVIR ETHANOLATE;  COBICISTAT,HUMAN PRESCRIPTION DRUG,1/31/2015,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (59676-575-30)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA]",N/A,No,12/31/2021
Symtuza,59676-0800-30,"800 mg/1,                         150  mg/1,                         200  mg/1,                         10  mg/1","TABLET, FILM COATED",ORAL,NDA210455,Janssen Products LP,59676-800,"Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide",DARUNAVIR;  COBICISTAT;  EMTRICITABINE;  TENOFOVIR ALAFENAMIDE,HUMAN PRESCRIPTION DRUG,7/17/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (59676-800-30)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Symtuza,59676-0800-99,"800 mg/1,                         150  mg/1,                         200  mg/1,                         10  mg/1","TABLET, FILM COATED",ORAL,NDA210455,Janssen Products LP,59676-800,"Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide",DARUNAVIR;  COBICISTAT;  EMTRICITABINE;  TENOFOVIR ALAFENAMIDE,HUMAN PRESCRIPTION DRUG,7/17/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (59676-800-99)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,Yes,12/31/2021
Dovato,49702-0246-61,"50 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA211994,ViiV Healthcare Company,49702-246,dolutegravir sodium and lamivudine,DOLUTEGRAVIR SODIUM;  LAMIVUDINE,HUMAN PRESCRIPTION DRUG,4/8/2019,N/A,NDA,"14 TABLET, FILM COATED in 1 BOTTLE (49702-246-61)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Dovato,49702-0246-13,"50 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA211994,ViiV Healthcare Company,49702-246,dolutegravir sodium and lamivudine,DOLUTEGRAVIR SODIUM;  LAMIVUDINE,HUMAN PRESCRIPTION DRUG,4/8/2019,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-246-13)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Juluca,49702-0242-13,"50 mg/1,                         25  mg/1","TABLET, FILM COATED",ORAL,NDA210192,ViiV Healthcare Company,49702-242,dolutegravir sodium and rilpivirine hydrochloride,DOLUTEGRAVIR SODIUM;  RILPIVIRINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,11/21/2017,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (49702-242-13)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Non-Nucleoside Analog [EXT]",N/A,No,12/31/2021
DELSTRIGO,00006-5007-01,"100 mg/1,                         300  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA210807,Merck Sharp & Dohme Corp.,0006-5007,"doravirine, lamivudine, and tenofovir disoproxil fumarate",DORAVIRINE;  LAMIVUDINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,7/20/2018,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (0006-5007-01)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Non-Nucleoside Analog [EXT], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Atripla,70518-0341-00,"600 mg/1,                         200  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021937,REMEDYREPACK INC.,70518-0341,"efavirenz, emtricitabine, and tenofovir disoproxil fumarate",EFAVIRENZ;  EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,3/20/2017,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (70518-0341-0)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Atripla,15584-0101-01,"600 mg/1,                         200  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021937,"Gilead Sciences, LLC",15584-0101,"efavirenz, emtricitabine, and tenofovir disoproxil fumarate",EFAVIRENZ;  EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,7/20/2006,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (15584-0101-1)","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
SYMFI,49502-0475-93,"600 mg/1,                         300  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA022142,Mylan Specialty L.P.,49502-475,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",EFAVIRENZ;  LAMIVUDINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,4/25/2018,N/A,NDA,"1 BOTTLE, PLASTIC in 1 CARTON (49502-475-93)  > 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
SYMFI LO,49502-0425-93,"400 mg/1,                         300  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA208255,Mylan Specialty L.P.,49502-425,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",EFAVIRENZ;  LAMIVUDINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,3/13/2018,N/A,NDA,"1 BOTTLE, PLASTIC in 1 CARTON (49502-425-93)  > 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC","Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Genvoya,61958-1901-01,"150 mg/1,                         150  mg/1,                         200  mg/1,                         10  mg/1",TABLET,ORAL,NDA207561,"Gilead Sciences, Inc.",61958-1901,"elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide",ELVITEGRAVIR;  COBICISTAT;  EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,11/5/2015,N/A,NDA,"30 TABLET in 1 BOTTLE, PLASTIC (61958-1901-1)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Genvoya,70518-0568-00,"150 mg/1,                         150  mg/1,                         200  mg/1,                         10  mg/1",TABLET,ORAL,NDA207561,REMEDYREPACK INC.,70518-0568,"elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide",ELVITEGRAVIR;  COBICISTAT;  EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,6/6/2017,N/A,NDA,30 TABLET in 1 BLISTER PACK (70518-0568-0),"HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Stribild,61958-1201-01,"150 mg/1,                         150  mg/1,                         200  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA203100,"Gilead Sciences, Inc.",61958-1201,"elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate",ELVITEGRAVIR;  COBICISTAT;  EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/27/2012,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1201-1)","HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
ODEFSEY,61958-2101-01,"200 mg/1,                         25  mg/1,                         25  mg/1",TABLET,ORAL,NDA208351,"Gilead Sciences, Inc.",61958-2101,"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide",EMTRICITABINE;  RILPIVIRINE HYDROCHLORIDE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,3/1/2016,N/A,NDA,"30 TABLET in 1 BOTTLE, PLASTIC (61958-2101-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Non-Nucleoside Analog [EXT], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
COMPLERA,61958-1101-01,"200 mg/1,                         25  mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA202123,"Gilead Sciences, Inc.",61958-1101,"emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate",EMTRICITABINE;  RILPIVIRINE HYDROCHLORIDE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/10/2011,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE (61958-1101-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Non-Nucleoside Analog [EXT], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
DESCOVY,61958-2002-02,"200 mg/1,                         25  mg/1",TABLET,ORAL,NDA208215,"Gilead Sciences, Inc.",61958-2002,emtricitabine and tenofovir alafenamide,EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,4/4/2016,N/A,NDA,30 TABLET in 1 BLISTER PACK (61958-2002-2),"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
DESCOVY,70518-0230-00,"200 mg/1,                         25  mg/1",TABLET,ORAL,NDA208215,REMEDYREPACK INC.,70518-0230,emtricitabine and tenofovir alafenamide fumarate,EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,2/16/2017,N/A,NDA,30 TABLET in 1 BLISTER PACK (70518-0230-0),"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
DESCOVY,61958-2002-01,"200 mg/1,                         25  mg/1",TABLET,ORAL,NDA208215,"Gilead Sciences, Inc.",61958-2002,emtricitabine and tenofovir alafenamide,EMTRICITABINE;  TENOFOVIR ALAFENAMIDE FUMARATE,HUMAN PRESCRIPTION DRUG,4/4/2016,N/A,NDA,"30 TABLET in 1 BOTTLE, PLASTIC (61958-2002-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,68071-2112-03,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"NuCare Pharmaceuticals,Inc.",68071-2112,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"3 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68071-2112-3)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Truvada,63629-7581-01,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,Bryant Ranch Prepack,63629-7581,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"3 TABLET, FILM COATED in 1 BOTTLE (63629-7581-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,63629-7581-02,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,Bryant Ranch Prepack,63629-7581,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"7 TABLET, FILM COATED in 1 BOTTLE (63629-7581-2)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,63629-7581-03,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,Bryant Ranch Prepack,63629-7581,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"15 TABLET, FILM COATED in 1 BOTTLE (63629-7581-3)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,70518-0097-01,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,REMEDYREPACK INC.,70518-0097,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,1/3/2017,N/A,NDA,"3 TABLET, FILM COATED in 1 BLISTER PACK (70518-0097-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,70518-0097-00,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,REMEDYREPACK INC.,70518-0097,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,1/3/2017,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (70518-0097-0)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,61958-0701-01,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"Gilead Sciences, Inc",61958-0701,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-0701-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,67296-1237-03,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"RedPharm Drug, Inc.",67296-1237,Truvada,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"3 TABLET, FILM COATED in 1 BOTTLE (67296-1237-3)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,61958-0704-01,"133 mg/1,                         200  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"Gilead Sciences, Inc",61958-0704,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,3/10/2016,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-0704-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,61958-0705-01,"167 mg/1,                         250  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"Gilead Sciences, Inc",61958-0705,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,3/10/2016,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-0705-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,61958-0703-01,"100 mg/1,                         150  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"Gilead Sciences, Inc",61958-0703,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,3/10/2016,N/A,NDA,"30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-0703-1)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
Truvada,67296-1237-04,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,"RedPharm Drug, Inc.",67296-1237,Truvada,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,8/2/2004,N/A,NDA,"4 TABLET, FILM COATED in 1 BOTTLE (67296-1237-4)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
TRUVADA,61919-0669-02,"200 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA021752,DIRECT RX,61919-669,emtricitabine and tenofovir disoproxil fumarate,EMTRICITABINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,2/22/2017,N/A,NDA,"2 TABLET, FILM COATED in 1 BOTTLE (61919-669-02)","Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2021
CIMDUO,49502-0450-93,"300 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA022141,Mylan Specialty L.P.,49502-450,Lamivudine and Tenofovir Disoproxil Fumarate,LAMIVUDINE;  TENOFOVIR DISOPROXIL FUMARATE,HUMAN PRESCRIPTION DRUG,6/25/2018,N/A,NDA,"1 BOTTLE, PLASTIC in 1 CARTON (49502-450-93)  > 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC","Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosides [CS], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
COMBIVIR,49702-0202-18,"150 mg/1,                         300  mg/1","TABLET, FILM COATED",ORAL,NDA020857,ViiV Healthcare Company,49702-202,lamivudine and zidovudine,LAMIVUDINE;  ZIDOVUDINE,HUMAN PRESCRIPTION DRUG,10/19/2010,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)","Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]",N/A,No,12/31/2020
Kaletra,55289-0947-12,"200 mg/1,                         50  mg/1","TABLET, FILM COATED",ORAL,NDA021906,"PD-Rx Pharmaceuticals, Inc.",55289-947,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,6/18/2010,N/A,NDA,"12 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55289-947-12)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Kaletra,00074-0522-60,"100 mg/1,                         25  mg/1","TABLET, FILM COATED",ORAL,NDA021906,AbbVie Inc.,0074-0522,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,6/18/2010,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (0074-0522-60)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Kaletra,70518-0091-02,"200 mg/1,                         50  mg/1","TABLET, FILM COATED",ORAL,NDA021906,REMEDYREPACK INC.,70518-0091,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,12/29/2016,N/A,NDA,"30 TABLET, FILM COATED in 1 BLISTER PACK (70518-0091-2)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Kaletra,00074-3956-46,"80 mg/mL,                         20  mg/mL",SOLUTION,ORAL,NDA021251,AbbVie Inc.,0074-3956,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,6/18/2010,N/A,NDA,1 BOTTLE in 1 CARTON (0074-3956-46)  > 160 mL in 1 BOTTLE,"HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Kaletra,00074-6799-22,"200 mg/1,                         50  mg/1","TABLET, FILM COATED",ORAL,NDA021906,AbbVie Inc.,0074-6799,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,6/18/2010,N/A,NDA,"120 TABLET, FILM COATED in 1 BOTTLE (0074-6799-22)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Kaletra,00074-6799-30,"200 mg/1,                         50  mg/1","TABLET, FILM COATED",ORAL,NDA021906,AbbVie Inc.,0074-6799,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,6/18/2010,N/A,NDA,"120 TABLET, FILM COATED in 1 BOTTLE (0074-6799-30)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,Yes,12/31/2021
Kaletra,00074-1575-21,"100 mg/1,                         25  mg/1","TABLET, FILM COATED",ORAL,NDA021906,AbbVie Inc.,0074-1575,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,4/8/2020,N/A,NDA,"60 TABLET, FILM COATED in 1 BOTTLE (0074-1575-21)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
Kaletra,00074-2605-21,"200 mg/1,                         50  mg/1","TABLET, FILM COATED",ORAL,NDA021906,AbbVie Inc.,0074-2605,Lopinavir and Ritonavir,LOPINAVIR;  RITONAVIR,HUMAN PRESCRIPTION DRUG,4/8/2020,N/A,NDA,"120 TABLET, FILM COATED in 1 BOTTLE (0074-2605-21)","HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Protease Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], P-Glycoprotein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], UDP Glucuronosyltransferases Inducers [MoA]",N/A,No,12/31/2021
